- KYPROLIS® (carfilzomib) is indicated in combination with dexamethasone or with lenalidomide plus dexamethasone or with daratumumab and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy. ... Read More
When multiple myeloma relapses,
Look to KYPROLIS®
for the way forward
DKd as a dual-
KRd as a triplet therapy
Kd as a doublet therapy
DKd = KYPROLIS®+Darzalex® (daratumumab) and dexamethasone; KRd = KYPROLIS®+lenalidomide and dexamethasone; Kd = KYPROLIS®+dexamethasone; Rd = lenalidomide+dexamethasone; Vd = Velcade® (bortezomib)+dexamethasone.